Vigilare Wealth Management Adaptimmune Therapeutics PLC Transaction History

Vigilare Wealth Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 10, 2023	SELL	$1.05 - $2.53 $8,400 - $20,240	-8,000 Reduced 21.74%	28,800 $0
Q3 2022 Oct 20, 2022	SELL	$1.06 - $2.41 $5,300 - $12,050	-5,000 Reduced 11.96%	36,800 $40,000
Q2 2022 Jul 11, 2022	BUY	$1.33 - $2.28 $55,594 - $95,303	41,800 New	41,800 $71,000
Q1 2022 Apr 06, 2022	SELL	$1.73 - $4.06 $170,318 - $399,706	-98,450 Closed	0 $0
Q4 2021 Jan 07, 2022	SELL	$3.5 - $5.68 $5,250 - $8,520	-1,500 Reduced 1.5%	98,450 $369,000
Q3 2021 Oct 19, 2021	BUY	$3.44 - $6.37 $157,208 - $291,109	45,700 Added 84.24%	99,950 $517,000
Q2 2021 Jul 16, 2021	BUY	$3.86 - $5.78 $65,041 - $97,393	16,850 Added 45.05%	54,250 $231,000
Q1 2021 Apr 29, 2021	BUY	$4.9 - $6.83 $97,510 - $135,917	19,900 Added 113.71%	37,400 $199,000
Q4 2020 Jan 14, 2021	BUY	$4.0 - $9.2 $70,000 - $161,000	17,500 New	17,500 $94,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $105M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Vigilare Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Vigilare Wealth Management with notifications on news.